SCHEMBL593134

SCHEMBL593134

O=COC(=O)c1ccc(O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.56
CA2 P00918 6/20 0.56
CA12 O43570 4/20 0.56
CA7 P43166 4/20 0.56
CA9 Q16790 4/20 0.56
CA14 Q9ULX7 4/20 0.56
ESR1 P03372 5/20 0.50
ESR2 Q92731 3/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 4/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
TSHR P16473 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CHRM1 P11229 1/20 0.47
SLC6A2 P23975 1/20 0.47
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402587 0.91 ALDH1A1 (0.46) CA1CA2CA12CA7CA9
SCHEMBL22191623 0.82 TSHR (0.55) CA1CA2CA12CA7CA9
SCHEMBL9330930 0.81 KMT2A (0.50) ESR1ESR2MEN1KMT2ATSHR
SCHEMBL9630702 0.80 CES2 (0.50) CA1CA2MEN1KMT2AMAPT
SCHEMBL15846817 0.80 LMNA (0.52) MEN1KMT2ALMNAMAPTPKM
SCHEMBL1377357 0.80 CES2 (0.50) CA1CA2MEN1KMT2ALMNA
SCHEMBL9364286 0.80 CES2 (0.50) CA1CA2ESR1ESR2MEN1
SCHEMBL10050028 0.80 TDP1 (0.59) MEN1KMT2ALMNAMAPTPKM
SCHEMBL689989 0.80 CA1 (0.54) CA1CA2CA12CA7CA9
SCHEMBL28748274 0.80 CA1 (0.59) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119280201-A Application of formylparanol mixed source terpenoid derivatives or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and treating liver lipid metabolism abnormality related diseases 中国药科大学 2025-01-10 CN claimed
CN-104945449-B Bioactive ingredients and its medical usage in Green Bamboo Leaf Liquor 石河子大学 2017-10-24 CN claimed
US-8114775-B2 Dihydroxy enol compounds used in chemical mechanical polishing compositions having metal ion oxidizers DUPONT AIR PRODUCTS NANOMATERIALS, LLC (US) 2012-02-14 US claimed
EP-1871855-B1 DIHYDROXY ENOL COMPOUNDS USED IN CHEMICAL MECHANICAL POLISHING COMPOSITIONS HAVING METAL ION OXIDIZERS DUPONT AIR PROD NANOMATERIALS (US) 2010-03-24 EP claimed
US-20090308836-A1 DIHYDROXY ENOL COMPOUNDS USED IN CHEMICAL MECHANICAL POLISHING COMPOSITIONS HAVING METAL ION OXIDIZERS VERSUM MATERIALS US, LLC 2009-12-17 US claimed
EP-1871855-A1 DIHYDROXY ENOL COMPOUNDS USED IN CHEMICAL MECHANICAL POLISHING COMPOSITIONS HAVING METAL ION OXIDIZERS DuPont Air Products NanoMaterials L.L.C. (US) 2008-01-02 EP claimed
US-20060270235-A1 Dihydroxy enol compounds used in chemical mechanical polishing compositions having metal ion oxidizers VERSUM MATERIALS US, LLC 2006-11-30 US claimed
WO-2006105020-A1 DIHYDROXY ENOL COMPOUNDS USED IN CHEMICAL MECHANICAL POLISHING COMPOSITIONS HAVING METAL ION OXIDIZERS DUPONT AIR PRODUCTS NANOMATERIALS LLC (US) 2006-10-05 WO claimed
US-20030082101-A1 Accelerators for increasing the rate of formation of free radicals and reactive oxygen species CAVALIER DISCOVERY 2003-05-01 US claimed
WO-2002100478-A9 ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES CAVALIER DISCOVERY (US) 2003-03-27 WO claimed
US-5621006-A TOPICALLY APPLYING IN A VEHICLE, E.G. HYDROXYACIDS, KETOACIDS AND SALTS, ESTERS THEREOF YU RUEY J (US) 1997-04-15 US claimed
EP-0599819-B1 Use of hydroxycarboxylic acids and derivatives for the preparation of topical dermatologic compositions for the treatment of wrinkles SCOTT EUGENE J VAN (US) 1997-04-02 EP claimed
US-5561157-A INCLUDES ORGANIC ALPHA AND BETA HYDROXY OR KETO CARBOXYLIC ACIDS, ESTERS, LACTONES AND/OR SALTS; USED FOR SKIN DISORDERS TRISTRATA INC (US) 1996-10-01 US claimed
US-5561158-A Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging TRISTRATA, INCORPORATED 1996-10-01 US claimed
US-5554654-A COMPRISING SALICYLIC ACID, RETINOIC ACID, ERYTHROMYCIN, METRONIDAZOLE, TETRACYCLINE, CLINDAMYCIN, MINOCYCLINE, MECLOCYCLINE OR BENZILIC ACID BY COMBINING WITH 2-HYDROXY ACID, 2-KETOACID, DERIVATIVE THEREOF OR RELATED COMPOUND TRISTRATA INC (US) 1996-09-10 US claimed
US-5554652-A TOPICALLY APPLYING MIXTURE TO REDUCE OR PREVENT SKIN DISORDERS TRISTRATA INC (US) 1996-09-10 US claimed
EP-0273202-B1 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. SCOTT EUGENE J VAN (US) 1995-06-21 EP claimed
EP-0599819-A2 Additives enhancing topical actions of therapeutic agents Van Scott, Eugene J., Dr. (US) 1994-06-01 EP claimed
CN-1031648-A Prevent mean that elastomeric material is made and manufacture method thereof HUTCHINSON (FR) 1989-03-15 CN claimed
EP-0273202-A2 Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. Van Scott, Eugene J., Dr. (US) 1988-07-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082101-A1 Accelerators for increasing the rate of formation of free radicals and reactive oxygen species SOD1, SOD3, APEX1 CA1 1349/4885CA2 493/4885CA12 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.